Breaking News Instant updates and real-time market news.

NKE

Nike

$53.70

0.47 (0.88%)

17:31
09/26/17
09/26
17:31
09/26/17
17:31

Nike: North America marketplace still undergoing 'significant' transformation

Says seeing "incredible" results in China. Says North America marketplace undergoing "significant" transformation. Says NA marketplace continues to be disrupted by shift to digital and want for further personal experience. Says has maintained to slightly increase market share in U.S. Says currently acting on category-specific methods to better reach consumers.

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

NKE Nike
$53.70

0.47 (0.88%)

09/19/17
BOFA
09/19/17
NO CHANGE
Target $42
BOFA
Underperform
Nike risk/reward remains unfavorable, says BofA/Merrill
BofA/Merrill analyst Robert Ohmes believes Nike to report Q1 earnings next Tuesday above consensus of 48c given conservative guidance but expects a muted outlook due to weakening data points. Ohmes said retail partner same-store sales have deteriorated from last quarter, SportScan data continues to deteriorate, the promotional environment remains elevated, the company continues to lose share to adidas, the e-commerce channel has become a "dumping ground" for clearance and discounting, and VaporMax sales are not yet meaningful. The analyst maintains his Underperform rating and $42 price target on Nike and said risk/reward remains unfavorable.
09/19/17
09/19/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Underperform from Market Perform at Wells Fargo with Wells Fargo with analyst Tom Nikic saying with consumers having filled their closets with athletic wear over the past seven years, the category "appears poised to take a breather for now." The analyst cut his price target for the shares to $13 from $17. 2. Kellogg (K) downgraded to Neutral from Overweight at Piper Jaffray with analyst Michael Lavery saying cereal could be at risk from shrinking center store space. 3. Nike (NKE) downgraded to Neutral from Positive at Susquehanna saying that his checks indicate that the North American and European businesses are decelerating as some key categories, especially basketball, have underperformed, resulting in excess inventory that will pressure sales and margins. 4. Synchronoss (SNCR) downgraded to Underperform from Outperform at Raymond James with analyst Tavis McCourt citing the news that Siris Capital is no longer interested in an all-cash transaction for all the outstanding shares of the company and has withdrawn its $18 per share bid from June 22. Further, the analyst believes it increasingly unlikely that the current strategic review will result in an acquisition at a premium and expects share to come under pressure and stay in the range prior to the Siris indication of interest. 5. Sony (SNE) downgraded to Neutral from Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/22/17
PIPR
09/22/17
NO CHANGE
Target $53
PIPR
Neutral
Nike bulls in denial about resurgence of adidas, Piper Jaffray says
Piper Jaffray analyst Erinn Murphy says her intra-quarter reads point to ongoing deceleration in Nike (NKE) momentum, increasing concern around the Jordan brand, which represents 10% of sales, and intensifying promotional pressure on the category domestically. Bulls on Nike are still denying the durability of adidas' (ADDYY) resurgence, Murphy tells investors in a pre-earnings research note. The analyst believes adidas' market share gains have "longer growth sustainability." For Nike's Q1 results on September 26, Murphy sees revenue as inline "at best" and gross margin worse than expected. The analyst, however, sees cost controls driving an earnings beat. Murphy also sees risk to Nike's outlook for Q2. She keeps a Neutral rating on the shares with a $53 price target.
09/26/17
BERN
09/26/17
NO CHANGE
BERN
Survey respondents more likely to buy Nike for fashion/function, says Bernstein
Bernstein analyst Jamie Merriman says he and his firm surveyed 1000 people in the U.S. in July, asking them about 22 athletic apparel and footwear brands. At the athletic apparel and footwear category level, 58% of survey respondents expect to spend about the same amount on the category as they have spent over the last 12 months, while 28% expect to spend more and 14% expect to spend less, he notes. Among those who had shopped the brands in the LTM, the analyst says theintention to purchase more in the NTM was similar across Nike (NKE), adidas (ADDYY) and Under Armour (UAA), while Lululemon (LULU) customers reported the highest intention to purchase more going forward. Additionally, Merriman said respondents were most likely to purchase Nike, relative to other brands, for a combination of fashion and function.

TODAY'S FREE FLY STORIES

GNRC

Generac

$50.49

-0.4 (-0.79%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Recommendations
Generac analyst commentary  »

Generac estimates raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

ADP

ADP

$113.72

-0.86 (-0.75%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Periodicals
Ackman increases pressure on ADP over tech development, WSJ reports »

Activist investor and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

PRKR

ParkerVision

$1.50

-0.06 (-3.85%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Hot Stocks
ParkerVision enters common stock purchase agreement with Aspire Capital »

ParkerVision announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$9.23

0.15 (1.65%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Technical Analysis
Technical View: GoPro trades higher, analyst action »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

NAVI

Navient

$12.20

0.47 (4.01%)

07:17
10/18/17
10/18
07:17
10/18/17
07:17
Hot Stocks
Navient sees adding over $1B of education refinance loans in FY17 »

Including the planned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Conference/Events
Commodity Futures Trading Commission Commissioners to speak at Expo »

Brian Quintenz and Rostin…

FGEN

FibroGen

$55.30

0.8 (1.47%)

, AZN

AstraZeneca

$34.78

0.13 (0.38%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Hot Stocks
FibroGen announces CFDA acceptance of roxadustat NDA »

FibroGen (FGEN) and its…

FGEN

FibroGen

$55.30

0.8 (1.47%)

AZN

AstraZeneca

$34.78

0.13 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 08

    Nov

  • 09

    Nov

CMG

Chipotle

$329.30

8.91 (2.78%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Technical Analysis
Technical View: Chipotle falls, analyst actions »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

UNH

UnitedHealth

$203.89

10.69 (5.53%)

, AMZN

Amazon.com

$1,009.13

2.79 (0.28%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Recommendations
UnitedHealth, Amazon.com analyst commentary  »

UnitedHealth price target…

UNH

UnitedHealth

$203.89

10.69 (5.53%)

AMZN

Amazon.com

$1,009.13

2.79 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 26

    Oct

  • 18

    Mar

AAN

Aaron's

$41.55

0.01 (0.02%)

07:15
10/18/17
10/18
07:15
10/18/17
07:15
Initiation
Aaron's initiated  »

Aaron's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

BMTC

Bryn Mawr Bank

$44.50

-0.1 (-0.22%)

, FCF

First Commonwealth

$13.94

-0.26 (-1.83%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Conference/Events
FDIC to hold a committee meeting »

The FDIC's Advisory…

BMTC

Bryn Mawr Bank

$44.50

-0.1 (-0.22%)

FCF

First Commonwealth

$13.94

-0.26 (-1.83%)

ONB

Old National Bancorp

$18.40

-0.05 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 24

    Oct

  • 25

    Oct

  • 06

    Nov

HCC

Warrior Met Coal

$24.04

0.51 (2.17%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Downgrade
Warrior Met Coal rating change  »

Warrior Met Coal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOH

Molina Healthcare

$61.54

1.68 (2.81%)

, UNH

UnitedHealth

$203.89

10.69 (5.53%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Periodicals
Health insurers prepare for enrollment drop amid ACA uncertainty, WSJ says »

As enrollment for 2018…

MOH

Molina Healthcare

$61.54

1.68 (2.81%)

UNH

UnitedHealth

$203.89

10.69 (5.53%)

CNC

Centene

$93.80

2.88 (3.17%)

WCG

WellCare

$174.03

6.11 (3.64%)

CI

Cigna

$187.20

2.21 (1.19%)

ANTM

Anthem

$187.26

3.5 (1.90%)

HNT

Health Net

HUM

Humana

$240.43

3.26 (1.37%)

AET

Aetna

$155.90

4.46 (2.95%)

EHTH

eHealth

$23.79

-0.61 (-2.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 31

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 14

    Dec

IBM

IBM

$146.54

-0.29 (-0.20%)

07:12
10/18/17
10/18
07:12
10/18/17
07:12
Recommendations
IBM analyst commentary  »

IBM reported 'best…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 15

    Nov

NVO

Novo Nordisk

$49.31

-0.01 (-0.02%)

07:12
10/18/17
10/18
07:12
10/18/17
07:12
Conference/Events
FDA Endocrinologic & Metabolic Drugs Advisory Committee to hold a meeting »

The Committee discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TSLA

Tesla

$355.75

5.15 (1.47%)

07:11
10/18/17
10/18
07:11
10/18/17
07:11
Periodicals
Tesla employees claim dismissals not performance related, CNBC reports »

Tesla is trying to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ATTU

Attunity

$6.90

0.12 (1.77%)

07:11
10/18/17
10/18
07:11
10/18/17
07:11
Hot Stocks
Attunity's Replicate adopted by large health insurance provider »

Attunity announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

MYGN

Myriad Genetics

$35.84

-0.26 (-0.72%)

07:10
10/18/17
10/18
07:10
10/18/17
07:10
Hot Stocks
Myriad Genetics BRACAnalysis CDx sPMA by FDA for review »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

MAIN

Main Street

$40.07

-0.1 (-0.25%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Hot Stocks
Main Street announces semi-annual supplemental cash dividend of 27.5c per share »

Main Street Capital is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

JNJ

Johnson & Johnson

$140.79

4.67 (3.43%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Recommendations
Johnson & Johnson analyst commentary  »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

IONS

Ionis Pharmaceuticals

$63.85

2.7 (4.42%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Hot Stocks
Ionis collaborates with Seventh Sense Biosystems in blood collection device »

Ionis Pharmaceuticals has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 26

    Oct

LRCX

Lam Research

$194.55

2.19 (1.14%)

07:08
10/18/17
10/18
07:08
10/18/17
07:08
Recommendations
Lam Research analyst commentary  »

Lam Research price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMRN

Immuron

$5.03

0.1 (2.03%)

07:06
10/18/17
10/18
07:06
10/18/17
07:06
Initiation
Immuron initiated  »

Immuron initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLRX

BioLineRx

$1.09

-0.065 (-5.63%)

, RHHBY

Roche

$31.45

0.27 (0.87%)

07:05
10/18/17
10/18
07:05
10/18/17
07:05
Hot Stocks
BioLineRx: Genentech initiates Phase 1b/2 trial for BL-8040 »

BioLineRx (BLRX)…

BLRX

BioLineRx

$1.09

-0.065 (-5.63%)

RHHBY

Roche

$31.45

0.27 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

  • 30

    Nov

CEVA

CEVA

$45.40

0.1 (0.22%)

07:05
10/18/17
10/18
07:05
10/18/17
07:05
Hot Stocks
CEVA and Brodmann17 partner for deep learning in edge devices »

CEVA and Broadmann17, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.